NZ522146A - Mammalian receptor-like proteins, designated DNAX cytokine receptor subunits (DCRS), in particular DCRS5 - Google Patents

Mammalian receptor-like proteins, designated DNAX cytokine receptor subunits (DCRS), in particular DCRS5

Info

Publication number
NZ522146A
NZ522146A NZ522146A NZ52214601A NZ522146A NZ 522146 A NZ522146 A NZ 522146A NZ 522146 A NZ522146 A NZ 522146A NZ 52214601 A NZ52214601 A NZ 52214601A NZ 522146 A NZ522146 A NZ 522146A
Authority
NZ
New Zealand
Prior art keywords
polypeptide
leu
cell
dcrs5
ser
Prior art date
Application number
NZ522146A
Other languages
English (en)
Inventor
Madaline Chirica
Robert A Kastelein
Kevin W Moore
Christi L Parham
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22753958&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ522146(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of NZ522146A publication Critical patent/NZ522146A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/975Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
NZ522146A 2000-05-10 2001-05-10 Mammalian receptor-like proteins, designated DNAX cytokine receptor subunits (DCRS), in particular DCRS5 NZ522146A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20342600P 2000-05-10 2000-05-10
PCT/US2001/015057 WO2001085790A2 (en) 2000-05-10 2001-05-10 Mammalian cytokine receptor subunit proteins, related reagents and methods

Publications (1)

Publication Number Publication Date
NZ522146A true NZ522146A (en) 2004-10-29

Family

ID=22753958

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ522146A NZ522146A (en) 2000-05-10 2001-05-10 Mammalian receptor-like proteins, designated DNAX cytokine receptor subunits (DCRS), in particular DCRS5

Country Status (25)

Country Link
US (7) US6756481B2 (enExample)
EP (3) EP1918377B1 (enExample)
JP (6) JP5073909B2 (enExample)
KR (1) KR100869621B1 (enExample)
CN (2) CN1575337A (enExample)
AT (1) ATE396264T1 (enExample)
AU (2) AU6135101A (enExample)
CA (1) CA2408571C (enExample)
CY (1) CY1108545T1 (enExample)
CZ (1) CZ304022B6 (enExample)
DE (1) DE60134136D1 (enExample)
DK (1) DK1287130T3 (enExample)
ES (1) ES2307618T3 (enExample)
HK (1) HK1049862B (enExample)
HU (1) HUP0302339A3 (enExample)
IL (2) IL152414A0 (enExample)
MX (1) MXPA02011081A (enExample)
NO (2) NO331408B1 (enExample)
NZ (1) NZ522146A (enExample)
PL (1) PL209128B1 (enExample)
PT (1) PT1287130E (enExample)
SI (1) SI1287130T1 (enExample)
SK (1) SK287984B6 (enExample)
WO (1) WO2001085790A2 (enExample)
ZA (1) ZA200208795B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030082734A1 (en) * 1999-06-01 2003-05-01 Dowling Lynette M. Mammalian receptor proteins; related reagents and methods
EP1188830B1 (en) 1999-06-02 2010-01-20 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein ,nr10
EP1221482B1 (en) * 1999-09-27 2005-12-28 Chugai Seiyaku Kabushiki Kaisha Hemopoietin receptor protein, nr12
US7422743B2 (en) 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
PL209128B1 (pl) * 2000-05-10 2011-07-29 Schering Corp Białko receptora spokrewnionego z receptorami cytokin oraz związane z nim produkty, sposoby i zastosowania
KR101053412B1 (ko) 2002-10-30 2011-08-01 제넨테크, 인크. Il―17 생성의 억제
EP1587834B1 (en) 2002-12-23 2011-07-06 Schering Corporation Uses of il-23 mammalian cytokine; related reagents
US20040219150A1 (en) * 2003-02-06 2004-11-04 Cua Daniel J. Uses of mammalian cytokine; related reagents
BRPI0408247A (pt) * 2003-03-10 2006-03-01 Schering Corp usos de antagonistas e agonistas de il-23 e reagentes relacionados
CA2525184C (en) * 2003-05-09 2012-10-30 Centocor, Inc. Il-23p40 specific immunoglobulin derived proteins, compositions, methods and uses
WO2005079837A1 (en) * 2004-02-17 2005-09-01 Schering Corporation Methods of modulating il-23 activity; related reagents
US20050287593A1 (en) 2004-05-03 2005-12-29 Schering Corporation Use of cytokine expression to predict skin inflammation; methods of treatment
US7501247B2 (en) * 2004-05-03 2009-03-10 Schering Corporation Method of treating skin inflammation
AR051444A1 (es) * 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
US7820168B2 (en) * 2004-12-20 2010-10-26 Schering Corporation Treatment of diabetes using antibodies to IL-23, IL-23 receptor and IL-17
EP3501537A1 (en) 2005-06-30 2019-06-26 Janssen Biotech, Inc. Anti-il23 antibodies, compositions, methods and uses
JP5193881B2 (ja) 2005-12-29 2013-05-08 セントカー・インコーポレーテツド ヒト抗il−23抗体、組成物、方法および用途
AU2007255753B2 (en) 2006-06-08 2013-01-17 Chugai Seiyaku Kabushiki Kaisha Preventive or remedy for inflammatory disease
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Il-23拮抗劑於治療感染之用途
NZ579297A (en) * 2007-02-28 2012-03-30 Schering Corp Combination therapy comprising an il-23 antagonist and a cytokine antagonist for treatment of immune disorders
AU2008219684B2 (en) 2007-02-28 2014-04-17 Merck Sharp & Dohme Corp. Engineered anti-IL-23R antibodies
RU2596397C2 (ru) 2007-12-05 2016-09-10 Чугаи Сейяку Кабусики Кайся Терапевтическое средство от зуда
SG190626A1 (en) 2008-05-05 2013-06-28 Novimmune Sa Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
WO2010027767A1 (en) * 2008-08-27 2010-03-11 Schering Corporation Engineered anti-il-23r antibodies
CA2759942A1 (en) * 2009-04-27 2010-10-07 Novartis Ag Composition and methods of use for therapeutic antibodies specific for the il-12 receptore betai subunit
CN102458437B (zh) * 2009-05-05 2015-06-10 诺维莫尼公司 抗il-17f抗体及其使用方法
PT2635601T (pt) 2010-11-04 2016-09-27 Boehringer Ingelheim Int Anticorpos anti-il-23
EP4039275A1 (en) 2012-05-03 2022-08-10 Boehringer Ingelheim International GmbH Anti-il-23p19 antibodies
US10507241B2 (en) 2014-07-24 2019-12-17 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of IL-23A related diseases
EA039598B9 (ru) 2014-09-03 2022-03-10 Бёрингер Ингельхайм Интернациональ Гмбх Соединение, нацеленное на ил-23а и фно-альфа, и его применение
IL307578A (en) 2015-02-04 2023-12-01 Boehringer Ingelheim Int Methods of treating inflammatory diseases
US20190269757A1 (en) 2018-03-05 2019-09-05 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
BR112021009287A2 (pt) 2018-11-20 2021-10-26 Janssen Biotech, Inc. Método seguro e eficaz para tratar psoríase com anticorpo específico anti-il-23
CN113874073A (zh) 2019-05-23 2021-12-31 詹森生物科技公司 用针对IL-23和TNFα的抗体的联合疗法治疗炎性肠病的方法
CN115768466A (zh) 2020-05-21 2023-03-07 詹森生物科技公司 用抗IL-23和TNFα抗体的联合疗法治疗炎性肠病的方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2031216A1 (de) 1969-06-19 1971-01-14 Citizen Watch Co Ltd , Tokio Tag und Datum Stellvorrichtung fur Uhren mit Kalender
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4659678A (en) 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4859609A (en) 1986-04-30 1989-08-22 Genentech, Inc. Novel receptors for efficient determination of ligands and their antagonists or agonists
US5789192A (en) 1992-12-10 1998-08-04 Schering Corporation Mammalian receptors for interleukin-10 (IL-10)
US5888774A (en) * 1994-12-19 1999-03-30 Cangene Corporation Recombinant DNA molecules and expression vectors for erythropoietin
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
JPH11273358A (ja) 1998-03-26 1999-10-08 Kawasaki Steel Corp 半導体記憶装置
US20030082734A1 (en) * 1999-06-01 2003-05-01 Dowling Lynette M. Mammalian receptor proteins; related reagents and methods
ES2322791T5 (es) * 1999-06-01 2013-11-29 Merck Sharp & Dohme Corp. Proteínas receptoras de mamíferos; reactivos y métodos relacionados
JP4505166B2 (ja) 1999-09-09 2010-07-21 シェーリング コーポレイション 哺乳動物インターロイキン−12p40およびインターロイキンb30、その組成物、抗体、薬学的組成物における使用
JP2008099690A (ja) 1999-09-27 2008-05-01 Chugai Pharmaceut Co Ltd 新規ヘモポエチン受容体蛋白質、nr12
EP1221482B1 (en) * 1999-09-27 2005-12-28 Chugai Seiyaku Kabushiki Kaisha Hemopoietin receptor protein, nr12
PL209128B1 (pl) * 2000-05-10 2011-07-29 Schering Corp Białko receptora spokrewnionego z receptorami cytokin oraz związane z nim produkty, sposoby i zastosowania

Also Published As

Publication number Publication date
US20120121601A1 (en) 2012-05-17
AU2001261351B2 (en) 2007-03-01
SK287984B6 (sk) 2012-08-06
US7964703B2 (en) 2011-06-21
CZ20023698A3 (cs) 2003-04-16
PL209128B1 (pl) 2011-07-29
AU6135101A (en) 2001-11-20
PT1287130E (pt) 2008-09-01
WO2001085790A3 (en) 2002-07-18
CZ304022B6 (cs) 2013-08-28
ATE396264T1 (de) 2008-06-15
US7510853B2 (en) 2009-03-31
US7749718B2 (en) 2010-07-06
EP1287130A2 (en) 2003-03-05
NO331408B1 (no) 2011-12-19
US20030017617A1 (en) 2003-01-23
WO2001085790A2 (en) 2001-11-15
HK1049862A1 (en) 2003-05-30
IL152414A0 (en) 2003-05-29
SK15742002A3 (sk) 2003-03-04
NO20025354L (no) 2003-01-10
EP1287130B1 (en) 2008-05-21
DK1287130T3 (da) 2008-09-01
JP2003532408A (ja) 2003-11-05
US20100261273A1 (en) 2010-10-14
JP2015110576A (ja) 2015-06-18
SI1287130T1 (sl) 2008-08-31
CA2408571C (en) 2014-04-29
NO20111147L (no) 2003-01-10
HK1049862B (en) 2008-08-01
US20050100917A1 (en) 2005-05-12
CN101654479A (zh) 2010-02-24
NO20025354D0 (no) 2002-11-08
US7411041B2 (en) 2008-08-12
EP2275548A1 (en) 2011-01-19
ES2307618T3 (es) 2008-12-01
HUP0302339A3 (en) 2011-01-28
US8110378B2 (en) 2012-02-07
CA2408571A1 (en) 2001-11-15
EP1918377A1 (en) 2008-05-07
JP2015057396A (ja) 2015-03-26
IL152414A (en) 2010-05-31
CY1108545T1 (el) 2014-04-09
KR100869621B1 (ko) 2008-11-21
KR20020092472A (ko) 2002-12-11
US20050100918A1 (en) 2005-05-12
PL365177A1 (en) 2004-12-27
DE60134136D1 (de) 2008-07-03
ZA200208795B (en) 2004-02-09
HUP0302339A2 (hu) 2003-10-28
EP1918377B1 (en) 2013-12-04
US6756481B2 (en) 2004-06-29
US20090060865A1 (en) 2009-03-05
US20110243842A1 (en) 2011-10-06
JP2012187111A (ja) 2012-10-04
MXPA02011081A (es) 2003-03-10
JP2012070740A (ja) 2012-04-12
JP5073909B2 (ja) 2012-11-14
EP1287130B2 (en) 2017-07-26
CN1575337A (zh) 2005-02-02
JP2008273961A (ja) 2008-11-13

Similar Documents

Publication Publication Date Title
CA2408571C (en) Mammalian receptor proteins; related reagents and methods
AU2001261351A1 (en) Mammalian receptor proteins; related reagents and methods
US20030092881A1 (en) Mammalian receptor proteins; related reagents and methods
CA2374391C (en) Mammalian receptor proteins; related reagents and methods
US20050106673A1 (en) Mammalian receptor proteins; related reagents and methods
AU2007202362B2 (en) Mammalian receptor proteins; related reagents and methods
HK1117192A (en) Mammalian cytokine receptor subunit proteins, related reagents and methods
HK1152072A (en) Mammalian cytokine receptor subunit proteins, related reagents and methods

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 10 MAY 2021 BY THOMSON REUTERS

Effective date: 20140320

EXPY Patent expired